Skip to main content

Table 1 Demographic and Clinical Characteristics of 25,330 Patients Hospitalized for CHF

From: Outcomes of patients hospitalized for acute decompensated heart failure: does nesiritide make a difference?

Variable

Received nesiritide (n = 2692)

Did not receive nesiritide (n = 22,638)

 

Number (%)

Number (%)

Demographic variables*

  

Race/Ethnicity

  

   Black

292 (10.9)

2438 (10.8)

   Hispanic

266 (9.9)

1570 (6.9)

   White

2125 (78.9)

18,512 (81.8)

   Other race

9 (0.3)

118 (0.5)

Low economic status

118 (4.4)

960 (4.2)

Medications

  

ACE inhibitors

1558 (57.9)

12,173 (53.8)

Angiotensin II receptor antagonists

574 (21.3)

3478 (15.4)

Diuretics

2658 (98.7)

21,650 (95.6)

Digoxin

1320 (49.0)

8925 (39.4)

Beta blockers

2114 (78.5)

13,849 (61.2)

Dobutamine

341 (12.7)

1131 (5.0)

Dopamine

315 (11.7)

1185 (5.2)

IV nitroglycerin

313 (11.6)

1762 (7.8)

Milrinone

150 (5.6)

272 (1.2)

Severity measures

  

APR-DRG Severity of Illness

  

1 or 2

1343 (49.9)

14,653 (64.7)

3

1077 (40.0)

6979 (30.8)

4

272 (10.1)

1006 (4.4)

APR-DRG Risk of Mortality

  

1 or 2

1618 (60.1)

16,716 (73.8)

3

781 (29.0)

4661 (20.6)

4

293 (10.9)

1261 (5.6)

Outcomes

  

Hospital mortality

126 (4.7)

679 (3.0)

Prolonged length of stay

1088 (40.4)

4973 (22.0)

Elevated pharmacy cost

1688 (62.7)

4640 (20.5)

Readmission within 31 days for cardiac condition

340 (12.6)

2318 (10.2)

  1. * Median age of patients who received nesiritide (range) = 74 years (20–100 years), median age of patients who did not receive nesiritide (range) = 76 years (18–105 years)